Literature DB >> 1331877

The course of autonomic neural function in chronic uraemic patients during haemodialysis treatment.

G Vita1, V Savica, R M Puglisi, L Marabello, G Bellinghieri, C Messina.   

Abstract

Autonomic function was followed in 19 patients with uraemia on chronic haemodialysis treatment over a period of 18 months. A smaller group of 12 patients were studied over 56 months. The battery of cardiovascular reflex tests included R-R interval variation test, deep breathing, Valsalva manoeuvre, heart rate, and blood pressure responses to standing and sustained handgrip. Two indices of autonomic function were measured: the autonomic score, and the confidence level on Bayesian analysis. There was great variability in the course of autonomic function over the period studied, with improvement occurring in some subjects and deterioration in others. In addition some patients did not develop any abnormality. Among those patients with uraemia and normal autonomic function at the start of the study, a deterioration occurred in 33-36% in the 18-month follow-up but in 62.5% in the 56-month follow-up. As a group there was no significant change in autonomic function during follow-up, although a clear trend to deterioration was found despite chronic haemodialysis treatment.

Entities:  

Mesh:

Year:  1992        PMID: 1331877

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  2 in total

1.  Comparison of autonomic function using Valsalva ratio and 30:15 postural ratio prior to and after haemodialysis treatment.

Authors:  S J Rosansky; R Rhinehart; D Whittman; S J Menachery
Journal:  Clin Auton Res       Date:  1995-06       Impact factor: 4.435

2.  Evidence of cardiovascular autonomic impairment in mitochondrial disorders.

Authors:  Rita Di Leo; Olimpia Musumeci; Cesare de Gregorio; Antonio Recupero; Patrizia Grimaldi; Corrado Messina; Sebastiano Coglitore; Giuseppe Vita; Antonio Toscano
Journal:  J Neurol       Date:  2007-11-09       Impact factor: 6.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.